Abstract:
Die Erfindung betrifft Verfahren zur Herstellung von lagerstabilen Lösungen aus Pelargonium-Extrakten, dadurch gekennzeichnet, dass die Sauerstoffmenge bei atmosphärischem Druck im Kopfraum des zur Lagerung der Lösung aus Pelargonium-Extrakten verwendeten Gebindes auf maximal 0,025 Volumenteile (bevorzugt 0,015 Volumenteile, besonders bevorzugt 0,005 Volumenteile) pro Volumenteil der Lösung reduziert wird, wobei der Gehalt an Proanthocyanidinen und an 2H-1-Benzopyran-2-onen nach 9 Monaten Lagerung bei 25 °C und einer relativen Luftfeuchtigkeit von 60% um jeweils maximal 10 Gew.-% (bevorzugt maximal 7 Gew.-%, besonders bevorzugt maximal 5 Gew.-%, insbesondere maximal 3 Gew.-%) verringert ist.
Abstract:
The present invention relates to a method of preparing a plant extract, with the exception of an extract of Ginkgo biloba, with a content of unpolar environmental contaminants which is reduced over that of the starting extract, characterized by the following process steps: (a) preparation of an aqueous-ketonic or aqueous-alcoholic solution of a starting extract, (b) (i) applying the solution to an adsorber resin and (ii) eluting the adsorber resin with an aqueous C 3 -C 6 -ketone of an aqueous C 1 -C 3 -alcohol, and/or (c) extracting the solution thus obtained, or the solution of the starting extract, with a C 5 -C 7 and hydrocarbon or mixtures thereof, and removal of the hydrocarbon phase, and (d) if appropriate, concentrating-drying the resulting solution to give a dry extract. The invention furthermore relates to a plant extract (liquid extract or spissum extract, but also dry extract) with a content of unpolar environmental contaminants which is reduced over that of the starting extract, obtainable by the method according to the invention, and to a composition comprising this plant extract (for example pharmaceutical, foodstuff or other preparations).
Abstract:
Die Erfindung betrifft Extrakte aus der Rinde von Corynanthe-Arten, insbesondere von Corynanthe pachyceras, sowie deren Verwendung zur Therapie und Prophylaxe von Erkrankungen der ableitenden Harnwege, von Sexualstörungen, von Fettstoffwechselstörungen, von Herz-Kreislauf-Erkrankungen und von akuten und chronischen Schmerzzuständen. Die Erfindung betrifft ferner diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen.
Abstract:
The invention relates to a method for producing an extract of Ginkgo biloba, having a content of non-polar plant ingredients and ecological non-polar foreign substances, reduced compared with the initial extract. Said method is characterised in that it comprises the steps of (a) producing an aqueous ketonic or aqueous alcoholic solution of a Ginkgo biloba initial extract and applying said solution to an adsorbent resin, (b) eluting the adsorbent resin with an aqueous C 3 -C 6 ketone or an aqueous C 1 -C 3 alcohol and (c), optionally, concentrating and drying the obtained extract solution into a dry extract. Said invention also relates to an extract (liquid or thick or dry extract) of Ginkgo biloba obtained by said method, said extract having a content of non-polar plant ingredients and ecological non-polar foreign substances, reduced compared with the initial extract.
Abstract:
The invention relates to the use of the trisubstituted benzopyranones of general formula (I), wherein R 6 , R 7 and R 8 independently represent H or SO 3 H, and to the physiologically acceptable salts thereof for use in the treatment or prophylaxis of pathological conditions that are related to oxidative stress and/or inflammatory reactions. The invention also relates to novel trisubstituted benzopyranones and to the physiologically acceptable salts thereof, and to plant extracts, drugs, dietetic food and pharmaceutical preparations containing said compounds.
Abstract:
Die Erfindung betrifft die Verwendung von Extrakten aus Wurzeln von Pelargonium sidoides und/oder Pelargonium reniforme zur Behandlung von AIDS und AIDS-assoziierten Infektionen verursacht durch andere Viren, Bakterien, insbesondere Mykobakterien, Pilze und Parasiten.
Abstract:
Described are 2H-1-benzopyran-2-ones (coumarin derivatives) of general formula (I) in which R is a hydroxyl group, a lower-alkoxy group, a cycloalkoxy group with 4 to 6 C-atoms or the alkyl- or arylsulphonyloxy group R -SO2O-; R and R , independently of each other, are hydrogen atoms, hydroxyl groups, lower-alkyl groups or cycloalkoxy groups with 4 to 6-atoms; R is a hydrogen atom, a lower-alkyl group with 1 to 4 C-atoms or a phenyl group; Y is a nitrogen atom, a CH group or a COH group; R is a phenyl, naphthyl, pyridinyl or pyrimidinyl group which may optionally be substituted by one or two C1-C5 alkyl groups, by one or two halogen atoms, by a halogen and C1-C5 alkyl together, by perfluoroalkyl with 1 to 3 C-atoms by C1-C5 alkoxy, by hydroxy, by methylenedioxy or by nitro; R is a lower-alkyl group, a cycloalkyl group with 4 to 6 C-atoms or a phenyl group which may optionally be substituted by one or two C1-C5 alkyl groups, by one or two halogens atoms, or by perfluoroalkyl with 1 to 3 C-atoms; and n = 1 to 4; plus their addition compounds with physiologically tolerated acids. Also described are methods of preparing these compounds, intermediates in their preparation and methods of preparing such intermediates. The coumarin derivatives described possess a neuroprotective and psychopharmacological action. The invention also concerns drugs containing these compounds.
Abstract:
The invention relates to special purpose extracts (liquid and dry extracts) from Epimedium species, methods for production thereof, medicaments and foodstuffs comprising the same, in particular, dietary products and adjuncts including Medical Food and Dietary Supplements and use of the special purpose extracts for the prophylaxis and treatment of disease states caused by a lack of oestrogen or by a dysregulation of sex hormone metabolism, in particular, oestrogen metabolism.
Abstract:
Die vorliegende Erfindung betrifft Verfahren zur Herstellung von Extrakten aus Pelargonium sidoides und/oder Pelargonium reniforme und deren Verwendung zur Behandlung von akuten und chronischen Entzündungserkrankungen und Infektionen.
Abstract:
The invention relates to novel 2H-1-pyran-2-ones of general formula (I), wherein R represents an alkyl radical with 2-5 C atoms, a cycloalkyl radical with 4-6 C atoms, a cycloalkyl radical with 4-8 C atoms or an alkoxy alkyl radical with a total of 3-5 C atoms and R represents a 2-(3, 4- methylene dioxyphenyl)ethyl radical or a 2-phenyl ethenyl radical substituted with R , R and R in positions 3, 4 and 5, whereby independently from each other R and R represent methoxy or ethoxy and R is a straight chain or branched alkoxy radical with 1-5 C atoms, an alkenyl radical with 3-5 C atoms, a cycloalkoxy radical with 4-6 C atoms, a cycloalkyl radical with 4-8 C atoms or an alkoxy alkoxy radical with a total of 3-5 C atoms. The invention also relates to a method for producing said compounds in addition to novel intermediate products and to a method for the production thereof. The novel pyranone derivatives have an anti-convulsive and/or anti-epileptic effect in addition to a neuroprotective effect or act against neurodegenerate diseases. The invention further relates to medicaments containing these compounds.